|
|
|
|
| 联合应用缬沙坦和氢氯噻嗪治疗轻至中度中国高血压患者 |
|
|
|
|
|
| Combination antihypertensive therapy with valsartan and hydrochlorothiazide in Chinese patients with mild-to-moderate hypertension |
|
|
|
|
|
| Sun N.-L., Zhu J.-R., Zhao Y., Tu Y.M., Zhu J.-R., Cai N.-S., Tang B., Sun N.-L., Wang H.-Y., Hao Y.-M., Wang B.-C., Yang K., Wang Jian-Gang J., Hu J., Zhang Z.-X., Huang L., Yu X.-J., Yang X.-C., Gao M.-M., Huang Y., Li Q., Wan Z., Sun Y.-M., Su H., Xu J 2009/5/29 18:39:20 |
|
|
【发表评论】
|
|
|
|
|
打印|
推荐给好友
|
|
|
Current Medical Research and Opinion, 2008, Volume 24, Issue 10
|
|
|
|
|
|
|
| Objectives: To compare the efficacy and safety of valsartan (VAL)/HCTZ 80/12.5 mg with VAL 80 mg in Chinese patients with mild-to-moderate essential hypertension not adequately controlled with VAL 80 mg alone. Research design and methods: This was a multicenter, double-blind, double-dummy, randomized, active-controlled, parallel-group trial. Patients (1175) with mild-to-moderate essential hypertension (mean sitting diastolic blood pressure [MSDBP] ≥ 95 and < 110 mmHg) from 26 centers in China received VAL 80 mg o.d. for 4 weeks, 864 patients whose MSDBP remained ≥ 90 and < 110 mmHg were randomized (1:1) to receive VAL80/HCTZ12.5 mg (n=429) or VAL80 mg (n=435) for 8 weeks. Main outcome measures: The efficacy variable was changed from baseline to endpoint in trough MSDBP. The secondary efficacy variables were changed in mean sitting systolic blood pressure (MSSBP), response rate, and control rate. Results: Significant reductions in MSDBP and MSSBP from baseline to endpoint were observed in both groups. There were significantly greater reductions in MSDBP (8.4 mmHg vs. 6.2 mmHg) and MSSBP (10.2 mmHg vs. 6.7 mmHg), higher response (64.2% vs. 52.5%) and control rates (53.9% vs. 40.9%) in the VAL80/HCTZ12.5 group as compared with the VAL80 group at endpoint (p<0.001). VAL80/HCTZ12.5 was equally effective in both age subgroups (≥ 65 and < 65 years) and was well tolerated. There were no deaths and the two serious adverse events reported were unrelated to study medication. Conclusion: In Chinese patents with mild-to-moderate essential hypertension not adequately controlled by VAL 80 mg alone, VAL80/ HCTZ12.5 mg combination was well tolerated and showed additional BP reduction. The limitations of this study were the inability to include an HCTZ arm as a control group and the short trial duration. © 2008 Informa UK Ltd. |
|
|
|
|
|
|
| Correspondence Address: Zhu, J.-R.; Department of Cardiology, Zhongshan Hospital, Fudan University, No. 180 Feng Lin Road, Shanghai 200032, China; email: zhu.junren@zs-hospital.sh.cn |
|
|
|
|
|
|
|
|
|
|
|
请登录后发表评论，点击此处登录。
|
|
|
 疾病资源中心
王燕燕 王曙
上海交通大学附属瑞金医院内分泌科
患者，女，69岁。2009年1月无明显诱因下出现乏力，当时程度较轻，未予以重视。2009年3月患者乏力症状加重，尿色逐渐加深，大便习惯改变，颜色变淡。4月18日入我院感染科治疗，诉轻度头晕、心慌，体重减轻10kg。无肝区疼痛，无发热，无腹痛、腹泻、腹胀、里急后重，无恶性、呕吐等。入院半月前于外院就诊，查肝功能：ALT 601IU/L，AST 785IU/L，TBIL 97.7umol/L，白蛋白 41g/L，甲状腺功能：游离T3 30.6pmol/L，游离T4 51.9pmol/L，心电图示快速房颤。
医学数据库
|
